Fig. 2.

Hepatic Arg2 improves whole-body metabolism and insulin sensitivity. a Experimental design to test the role of Arg2 in protection from HFrD feeding. b, c Body weight (b) and echoMRI analysis of body composition (c) of AAV8-Control or AAV8-Arg2 WT mice fed NCD (n = 6–7 mice per group) or HFrD (n = 8 mice per group). d Indirect calorimetric quantification of VO₂, VCO₂, RER, and energy expenditure during light and dark cycles in AAV8-control and -Arg2 mice fed the indicated diet (n = 6 mice for NCD groups and n = 8 mice for HFrD groups). e Serum insulin (left), serum glucose (middle), and HOMA2 IR (right) in AAV8-control and -Arg2 mice fed NCD or HFrD. f Intraperitoneal glucose tolerance test (GTT) and insulin tolerance test (ITT) (n = 5 mice per group). g Hepatic mRNA expression of insulin-responsive genes. For box plots, the midline represents the median, boxes represent the interquartile range and whiskers show the full range of values. For bar graphs, data represent mean+s.e.m. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.0001 relative to vehicle treatment, by two-tailed Student’s t-test